EMG
ACAD icon

Ellington Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Ellington Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,900
Closed -$292K – 42
2020
Q1 		$292K Sell
6,900
-700
-9% -$28.8K 0.07% 335
2019
Q4 		$325K Sell
7,600
-400
-5% -$17.4K 0.07% 284
2019
Q3 		$288K Buy
+8,000
New +$243K 0.05% 381
2017
Q1 		– Sell
-19,200
Closed -$554K – 655
2016
Q4 		$554K Buy
+19,200
New +$508K 0.08% 197

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ellington Management Group's ACAD Position: Q2 2020 in Review

Ellington Management Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 6,900 shares — an estimated $292K sold.

Ellington Management Group first reported a position in ACAD in Q4 2016 and held it in 4 quarters. The position peaked at $554K in Q4 2016. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Ellington Management Group reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 6,900 Acadia Pharmaceuticals shares in Q2 2020, an estimated $292K.
  • Ellington Management Group first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Ellington Management Group's Acadia Pharmaceuticals position peaked at $554K in Q4 2016.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.